10x GenomicsTXG +2.54%60 Net Current Asset Value is $3.63 as of Mar. 2026, which is 76% below its 10-year median of 15.00. GuruFocus rates TXG with a GF Score™ of 60/100 and a GF Value™ of $18.96 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 273 Healthcare Providers & Services companies, 10x Genomics ranks worse than 69.96% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
10x Genomics's net current asset value per share for the quarter that ended in Mar. 2026 was $3.63.
The historical rank and industry rank for 10x Genomics's Net Current Asset Value or its related term are showing as below:
TXG'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.81 Med: 15 Max: 38.47
Current: 11.02
During the past 9 years, the highest Price-to-Net-Current-Asset-Value Ratio of 10x Genomics was 38.47. The lowest was 2.81. And the median was 15.00.
TXG's Price-to-Net-Current-Asset-Value is ranked worse than 69.96% of 273
companies
in the Healthcare Providers & Services industry
Industry Median: 6.11
vs TXG: 11.02
10x Genomics (NAS:TXG) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
10x Genomics Net Current Asset Value Related Terms
10x Genomics Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TXG vs DOCS, WAY, PRVA: Net Current Asset Value Comparison
For the Health Information Services subindustry, 10x Genomics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Price-to-Net-Current-Asset-Value vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $3.63 mean?
10x Genomics (TXG) has a Net Current Asset Value of $3.63 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on 10x Genomics and its competitors. This is 76% below median its historical median of 15.00. Over the past decade, 10x Genomics' Net Current Asset Value has ranged from 2.81 to 38.47. According to the industry distribution chart, 10x Genomics ranks #191 out of 273 companies in the Healthcare Providers & Services industry, placing it in the top 70%.
Is 10x Genomics' Net Current Asset Value too high?
10x Genomics' current Net Current Asset Value of $3.63 is 76% below median its 10-year median of 15.00. Over the past 10 years, this metric has ranged from a low of 2.81 to a high of 38.47. The Healthcare Providers & Services industry median Net Current Asset Value is 6.11. 10x Genomics' value of $3.63 is 40.6% below this industry median. Based on the distribution chart, 10x Genomics ranks #191 out of 273 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, 10x Genomics has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Net Current Asset Value compare to DOCS and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #191 out of 273 companies for Net Current Asset Value. This places 10x Genomics in the lower half of its industry. The industry median Net Current Asset Value is 6.11. 10x Genomics' value of $3.63 is 40.6% below this benchmark. Historically, 10x Genomics' own Net Current Asset Value has ranged from 2.81 to 38.47 over the past decade. While the company's 10-year median is 15.00 vs. the industry median of 6.11, 10x Genomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Healthcare Providers & Services company?
The median Net Current Asset Value among Healthcare Providers & Services companies is 6.11, based on 273 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current Net Current Asset Value of $3.63 is 40.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Net Current Asset Value is 6.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Net Current Asset Value is $3.63, which is 76% below median its own 10-year median of 15.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.96, compared to a current price of $40.00 — trading 111% above its estimated fair value. The current Net Current Asset Value is $3.63, which is 76% below median its 10-year median of 15.00 and 40.6% below the Healthcare Providers & Services industry median of 6.11. 10x Genomics' overall GF Score™ is 60/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For 10x Genomics (TXG), the current Net Current Asset Value is $3.63 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $40.00 is trading 111% above its estimated GF Value™ of $18.96.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Net Current Asset Value: $3.63 (76% below median its 10-year median of 15.00)
GF Value™: $18.96 vs. price of $40.00 (111% above fair value)
Industry Position: 40.6% below the Healthcare Providers & Services median (#191 of 273)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
60GF Score
Get the complete analysis for TXG
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
